Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Reumatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Two Different Doses of BMS-188667 Administered Intravenously to Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate
INTERVENTIONAL
Inicio: 1 de oct de 2000
ID: NCT00162266
Completado
Fase 3
ClinicalTrials.gov
A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
INTERVENTIONAL
Inicio: 18 de mar de 2013
ID: NCT01500551
Reclutando
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy.
INTERVENTIONAL
Inicio: 29 de jun de 2024
ID: NCT06015737
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1
INTERVENTIONAL
Inicio: 27 de abr de 2017
ID: NCT03104400
Completado
Fase 3
ClinicalTrials.gov
A MULTICENTER, OPEN LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF TOCILIZUMAB GIVEN SUBCUTANEOUSLY IN MONOTHERAPY AND IN COMBINATION WITH NON-BIOLOGIC DMARDS IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN LATIN AMERICA
INTERVENTIONAL
Inicio: 1 de jul de 2014
ID: NCT02011334
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination With Methotrexate (MTX) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy
INTERVENTIONAL
Inicio: 8 de ago de 2016
ID: NCT02886728
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled Extension Study to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
INTERVENTIONAL
Inicio: 21 de may de 2024
ID: NCT06133972
Reclutando
Fase 3
ClinicalTrials.gov
A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.
INTERVENTIONAL
Inicio: 28 de jul de 2025
ID: NCT06858319
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 26 de oct de 2021
ID: NCT04963296
Activo, no recluta
Fase 4
ClinicalTrials.gov
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
INTERVENTIONAL
Inicio: 30 de ago de 2021
ID: NCT04929210
Completado
Fase 2
ClinicalTrials.gov
A TWINSS Extension Trial to Evaluate the Safety and Tolerability of CFZ533 (Iscalimab) at Two Dose Levels Administered Subcutaneously in Patients With Sjögren's Syndrome
INTERVENTIONAL
Inicio: 5 de ene de 2021
ID: NCT04541589
Completado
Fase 3
ClinicalTrials.gov
A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
INTERVENTIONAL
Inicio: 1 de ene de 2008
ID: NCT00559585
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
INTERVENTIONAL
Inicio: 14 de jul de 2025
ID: NCT07015983
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis
INTERVENTIONAL
Inicio: 20 de sept de 2021
ID: NCT04886258
Completado
Fase 2
ClinicalTrials.gov
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone
INTERVENTIONAL
Inicio: 8 de oct de 2013
ID: NCT01894516
Terminado
Fase 2
ClinicalTrials.gov
A Phase II, Open-Label Extension Study of Patients Previously Enrolled in Study GA30044 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 9 de ene de 2018
ID: NCT03407482
Completado
Fase 2
ClinicalTrials.gov
An Open-Label Long-term Safety Extension Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC)
INTERVENTIONAL
Inicio: 1 de abr de 2011
ID: NCT01305746
Terminado
Fase 2
ClinicalTrials.gov
A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects With Lupus Nephritis
INTERVENTIONAL
Inicio: 1 de nov de 2013
ID: NCT01930890
Completado
Fase 1
ClinicalTrials.gov
A Randomized, Double-blind, Parallel Groups, Phase 1 Clinical Study Comparing the Pharmacokinetic, Safety and Immunogenicity of Adalimumab in Healthy Subjects
INTERVENTIONAL
Inicio: 1 de ago de 2022
ID: NCT06291948
Completado
Fase 2
ClinicalTrials.gov
A 24-week, Dose-ranging, Multicenter, Double-blind, Double-dummy, Active-controlled Core Study to Evaluate Canakinumab for Prophylaxis of Signs and Symptoms of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy and a 24-week Open-label, Multicenter Extension Study to Assess Safety, Tolerability and Efficacy of Canakinumab in Patients With Gout Who Are Given Canakinumab at the Time of Gout Flare
INTERVENTIONAL
Inicio: 1 de dic de 2008
ID: NCT00819585
Anterior
1
...
7
8
9
...
434
Siguiente
Filtros